BOOST Pharma has appointed Elaine Jones as Chair of its Board of Directors.
Having served on over 35 company boards during her career, Jones brings more than 20 years of experience to the role.
Her previous roles include Vice President of Venture Capital at Pfizer Ventures and multiple leadership roles at GSK’s corporate venture fund, SR One.
The appointment comes as BOOST advances its cell therapy for brittle bone disease, BT-101, towards phase 3 clinical development.
Hans Schambye, CEO of BOOST Pharma, said: “Elaine’s unique combination of strategic insight, investment acumen and deep board leadership experience will be invaluable as we prepare BT‑101 for late‑stage development.”
Jones is currently Chair of Mironid and a member of the Board of the Novartis Venture Fund.
Elaine Jones, incoming Chair of BOOST Pharma, said: “I look forward to supporting BOOST as it advances this promising therapy into late‑stage development.”